Fibromyalgia is a chronic disease that mainly affects women. The constant muscle and joint pain that characterizes them appears to be the work of the brain, but a recent study explored another avenue: autoimmunity.
About 2% of the European population is affected, most of whom are womenIt is a poorly understood chronic disease characterized by Muscles and joints, general fatigue, sleep disturbances, poor mental health, are prone to anxiety and depression. The feeling of constant pain, exacerbated by cold, stress, or humidity, is associated with malfunctions in pain circuits in the brain and peripheral nervous system. Some patients also experience a deregulation of the immune system.
This is an immunogen Swedish and English researchers interested. They wondered whether autoantibodies, which attack the self, could be involved in From Disease keys. They publish the results of their experiments with mice in .
Passing fibromyalgia to mice
The hypothesis presented in this publication is as follows. While autoantibodies, specifically IgGs, have a role in fibromyalgia, healthy mice should show symptoms if they are injected with them. So they received an injectionof people with fibromyalgia that contain only IgG.
The after this injection. They become more sensitive to cold or to mechanical stimuli, lose their vitality. Conversely, the serum of healthy subjects, or patients who lacked IgG, did not make the mice sick.Developed
Association between autoantibodies and pain
How do these antibodies work? According to the authors’ conclusions, they do not activate, but it is fixed to The satellites, among other things, are located in the spinal ganglion of the rat. tests in the laboratory It also showed that these autoantibodies can also bind to them in humans.
Thus, autoantibodies isolated from patients with fibromyalgia sensitize pain receptors located in the peripheral nervous system. They become hyperresponsive to stimuli and send pain signals to the brain.
There is currently no treatment to cure the cause of fibromyalgia. Support comes to and the , but it does not work for many patients. A better understanding of the effects of immunology on this disease could open up new therapeutic avenues. Treatments aimed at reducing the amount of IgG in the serum, such as plasmapheresis, can improve the lives of patients, who are often deficient.